Bayer has filed for approval in the US for elinzanetant as a non-hormonal treatment for menopausal symptoms such as hot flushes, with a rival therapy from Astellas in its sights. The FDA ...

Armed with new phase 3 data, Bayer has started preparing filings for elinzanetant as a treatment for vasomotor symptoms (VMS) associated with menopause, setting up a challenge to Astellas’ first ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

DelveInsight's “Menopause Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding ...

Common causes of headaches in travelers include dehydration, sleep deprivation, excessive alcohol intake and medication noncompliance. Patients with history of chronic headache often have ...

An expert discusses the management plan for patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), highlighting approaches beyond pharmacotherapies. An expert ...